The estimated Net Worth of Narinderjeet Singh is at least $0 dollars as of 8 May 2019. Mr. Singh owns over 7,291 units of Genocea Biosciences Inc stock worth over $0 and over the last 6 years he sold GNCA stock worth over $0. In addition, he makes $0 as Senior Vice President - Pharmaceutical Sciences and Manufacturing at Genocea Biosciences Inc.
Narinderjeet has made over 3 trades of the Genocea Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,291 units of GNCA stock worth $3,937 on 8 May 2019.
The largest trade he's ever made was exercising 7,291 units of Genocea Biosciences Inc stock on 8 May 2019 worth over $3,937. On average, Narinderjeet trades about 3,646 units every 9 days since 2019. As of 8 May 2019 he still owns at least 61,873 units of Genocea Biosciences Inc stock.
You can see the complete history of Mr. Singh stock trades at the bottom of the page.
Narinderjeet Singh serves as Senior Vice President - Pharmaceutical Sciences and Manufacturing of the Company. Mr. Narinder manages the manufacturing process development and manufacturing of Genocea’s products. Narinder has extensive experience in process development, scale-up, technical operations, and manufacturing supply chain of biopharmaceuticals. Prior to joining Genocea, Narinder served as Vice President of Drug Product Development and Manufacturing at Momenta Pharmaceuticals from July 2015 to March 2018, responsible for process development and manufacturing of drug products for Momenta’s biosimilars and novel product portfolio. Prior to Momenta, Narinder served as Director, Drug Product Technology at Amgen from June 2007 to July 2015, responsible for process development, commercialization, manufacturing and new technology development for drug products development of Amgen’s biologics-based portfolio. He began his career at Amgen functioning in various junior technical roles, beginning in 1997. Narinder received an Integrated B.Tech/M.Tech. in Biochemical Engineering and Biotechnology from the Indian Institute of Technology, Delhi in 1995, an M.S. in Chemical Engineering from the University of Houston, and an M.B.A. from UCLA Anderson School of Management.
Narinderjeet Singh is 48, he's been the Senior Vice President - Pharmaceutical Sciences and Manufacturing of Genocea Biosciences Inc since 2018. There are 13 older and 3 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.
Narinderjeet's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: